At this point, we haven't, and the main reason we haven't is that we're finding it very difficult to conduct that kind of analysis, mainly because the types of changes we will see with the changes to the Patent Act, particularly for the additional two years of protection, are not likely to kick in until the agreement has been in place for probably eight years or so—at least for the majority of the changes.
That means it's really impossible to predict whether there will be blockbuster drugs coming through at that point, whether there will be more biologics, and whether there will be more niche drugs that are going to have smaller but more targeted markets. We don't know what pricing policies may be on the drug side by that point, particularly in relation to comparisons between brand-name drugs and generic drugs. We have found that, at least at this point, it is very difficult to come up with any kind of clear prediction.
The other element I will add is that there are also, as I'm sure you're aware, some ongoing efforts to modify or reform the domestic system as well. The work that Health Canada is doing with the provinces on health care programs is likely to reduce some of the costs overall.